Other languages Aptevo Therapeutics Inc.

Equities

APVO

US03835L3069

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.3129 ^USD	-5.47%		+7.19%	-96.07%

Jul. 01	Aptevo Therapeutics Inc. announced that it has received $2.75 million in funding	CI
Jun. 28	Aptevo Shares Decline After Pricing of $2.8 Million Stock Offering	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Aptevo Shares Decline After Pricing of $2.8 Million Stock Offering	Jun. 28
Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
US Equity Markets Close Mixed After March Producer Price Inflation Data	Apr. 11
Top Midday Decliners	Apr. 11
Top Premarket Decliners	Apr. 11
Aptevo Therapeutics Inc. Provides Pipeline Update	Apr. 10
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	Mar. 07
Aptevo Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05
Aptevo Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Aptevo Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Aptevo Therapeutics Prices Offering of 8 Million Shares, Expects $5 Million Gross Proceeds	23-08-02
Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML	23-07-18
Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
XOMA Acquires Commercial Payment, Portion of Milestone Rights to Ixinity For $9.6 Million	23-03-30
Aptevo Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30
Aptevo Therapeutics Inc. Appoints Jeffrey G. Lamothe to Executive Vice President, Chief Operating Officer	23-03-07
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial	23-02-13
Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors	23-01-09
Sector Update: Health Care Stocks Carried Higher with Broader Markets	22-12-12
Sector Update: Health Care	22-12-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aptevo Therapeutics Inc.

Equities

APVO

US03835L3069

Other languages

Filters